MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-MP-23-0009883
Market Cap
₹63.97 Cr
ZENITHDRUG-SM · NSE
Share Price
₹37.00
-0.80% today
Revenue
₹132 Cr
FY 2023-24 · +14.9% YoY
EBITDA
₹15.46 Cr
Margin 11.8%
Net Profit
₹10.52 Cr
FY 2023-24 · +116.0% YoY
P/E (TTM)
7.1x
P/B 1.2x
ROE
24.1%
ROCE 25.2%
Debt / Equity
0.63
Interest cover 21.2x
About Zenith Drugs Limited
Data last updated:
Zenith Drugs Limited is a public limited company based in Indore, Madhya Pradesh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 15 November 2000 and has been in existence for over 26 years.
The company is registered with the Registrar of Companies (ROC), Gwalior, under CIN L24231MP2000PLC014465. Its GSTIN is 23AAACZ1475F1ZI (Madhya Pradesh). The company holds 6 GST registrations, of which 4 are active. It is a listed company as per MCA records. Its shares are listed on NSE: ZENITHDRUG.
The company has an authorised share capital of ₹22.4 Cr and a paid-up capital of ₹17.15 Cr. It is led by directors including Sandeep Bhardwaj (Managing Director) and Bhupesh Soni.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at K. No. 72/5 Village Muradpura, Indore, Madhya Pradesh, India – 453001.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹171.22 Cr, a growth of 28.4% compared to the previous year. For the same year it recorded a net profit of ₹4.1 Cr (net margin 2.4%) and EBITDA of ₹11.94 Cr (EBITDA margin 7%). The net worth stands at ₹73.32 Cr (up 5.7% YoY). Total assets are valued at ₹128.43 Cr (up 8.9% YoY).
The company has about 99 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Zenith Drugs. As per MCA filings, the company has open charges of ₹117.89 Cr and satisfied charges of ₹109.84 Cr on record. Court records list 7 cases involving the company, including 4 filed by the company and 3 filed against it; 6 cases are pending. The company has 1 deal on record (1 ipo); the latest was in February 2024. Its 10 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 5 smaller; the largest is M.M. Remedies Private Limited with revenue of ₹137.33 Cr. The company has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 218 overdue payments to 12 micro and small suppliers.
Zenith Drugs Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MP-23-0009883). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website zenithdrugs.com.
Company details
CIN L24231MP2000PLC014465
Registration Number 014465
Incorporation Date 15 November 2000
ROC Gwalior
Listing Status Listed (NSE: ZENITHDRUG)
Company Status Active
Date of Last AGM 29 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MP-23-0009883
CIN history
Zenith Drugs has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24231MP2000PLC014465, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24231MP2000PLC014465 | Current |
| U24231MP2000PTC014465 | Previous |
| U24231MP2000PLC014465 | Previous |
Recognitions & Rankings of Zenith Drugs
Contact details
Zenith Drugs Limited's registered office is in Depalpur, Madhya Pradesh.
- Social Media
- Registered AddressK. No. 72/5 Village Muradpura, Indore, Madhya Pradesh, India – 453001
- IndustryPharma, Drug Formulation & Development
Comprehensive company report
Zenith Drugs Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Zenith Drugs operates one associated brand: Zenith Drugs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Oral rehydration salts and medicaments are manufactured for healthcare needs. | zenithdrugs.com |
Business activity
The main business activities of Zenith Drugs are manufacturing and trade. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and wholesale trading. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | |
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Zenith Drugs Limited, buy the company report.
Financials of Zenith Drugs Limited
FY 2025-26 filings availableZenith Drugs Limited reported revenue of ₹171.22 Cr (up 28.4% YoY) for FY 2025-26.
Financial Highlights
FY 2023-24 · ConsolidatedRevenue
₹132 Cr
+14.9% YoY
EBITDA
₹15.46 Cr
+70.8% YoY
Profit After Tax
₹10.52 Cr
+116.0% YoY
Net Worth
₹62.27 Cr
+251.4% YoY
Total Assets
₹86.97 Cr
+98.3% YoY
Total Debt
₹24.64 Cr
-5.6% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|
| Income statement | |||
| Revenue | 132 | 115 | 91.66 |
| Revenue growth | +14.9% | +24.9% | - |
| EBITDA | 15.46 | 9.05 | 6.96 |
| EBITDA margin | +11.8% | +7.9% | +7.6% |
| Profit before tax | 13.44 | 6.65 | 4.40 |
| Net profit | 10.52 | 4.87 | 3.13 |
| Net profit margin | +8.0% | +4.3% | +3.4% |
| EPS (₹) | 5.59 | 122.02 | 78.46 |
| Balance sheet | |||
| Total assets | 86.97 | 43.85 | 30.98 |
| Net worth | 62.27 | 17.72 | 12.09 |
| Total debt | 24.64 | 26.11 | 18.81 |
| Cash & bank | 8.80 | 0.28 | 3.00 |
| Net working capital | 65.25 | 30.01 | 16.21 |
| Cash flow | |||
| Cash from operations | (13.01) | (4.77) | 5.15 |
| Cash from investing | 26.00 | (0.27) | (5.24) |
| Cash from financing | (4.47) | 4.99 | 1.24 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 171 | 133 | 132 | 115 | 91.66 | 73.40 | 78.27 |
| Revenue growth | +28.4% | +1.3% | +14.9% | +24.9% | +24.9% | -6.2% | - |
| EBITDA | 11.94 | 13.34 | 15.47 | 9.05 | 7.01 | 7.19 | 7.04 |
| EBITDA margin | +7.0% | +10.0% | +11.8% | +7.9% | +7.7% | +9.8% | +9.0% |
| Profit before tax | 5.38 | 9.27 | 13.29 | 6.66 | 4.41 | 4.59 | 4.87 |
| Net profit | 4.10 | 7.36 | 10.65 | 4.88 | 3.22 | 3.06 | 3.39 |
| Net profit margin | +2.4% | +5.5% | +8.1% | +4.3% | +3.5% | +4.2% | +4.3% |
| EPS (₹) | 2.30 | 4.18 | 5.56 | 122.03 | 80.32 | 76.66 | 85.00 |
| Balance sheet | |||||||
| Total assets | 128 | 118 | 86.15 | 43.15 | 29.64 | 25.12 | 18.64 |
| Net worth | 73.32 | 69.38 | 62.22 | 17.73 | 12.85 | 9.64 | 6.57 |
| Total debt | 55.10 | 48.57 | 23.94 | 25.42 | 16.79 | 15.48 | 12.07 |
| Cash & bank | 0.26 | 0.26 | 8.74 | 0.20 | 2.89 | 1.85 | 0.44 |
| Net working capital | 69.86 | 68.94 | 64.81 | 30.18 | 17.46 | 14.71 | 9.73 |
| Cash flow | |||||||
| Cash from operations | 8.87 | (5.47) | (15.84) | (4.27) | 4.91 | (0.89) | 3.48 |
| Cash from investing | (13.71) | (31.41) | (5.33) | (2.05) | (3.04) | (2.22) | (4.93) |
| Cash from financing | 4.83 | 28.39 | 29.72 | 6.30 | (0.83) | 2.88 | 1.36 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 30 Oct 2026
| Particulars | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|
| Revenue | 132 | 115 | 91.66 |
| Revenue growth | +14.9% | +24.9% | - |
| Other income | 2.28 | 1.24 | 1.01 |
| Total expenses | 116 | 105 | 84.70 |
| Employee cost | 5.34 | 4.09 | 2.84 |
| EBITDA | 15.46 | 9.05 | 6.96 |
| EBITDA margin | +11.8% | +7.9% | +7.6% |
| Depreciation | 1.30 | 1.31 | 1.33 |
| Interest | 3.00 | 2.33 | 2.24 |
| Profit before tax | 13.44 | 6.65 | 4.40 |
| Tax | 3.79 | 1.78 | 1.28 |
| Net profit | 10.52 | 4.87 | 3.13 |
| Net profit margin | +8.0% | +4.3% | +3.4% |
| EPS (₹) | 5.59 | 122.02 | 78.46 |
| Particulars | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 17.15 | 0.40 | 0.40 |
| Reserves & surplus | 45.12 | 17.32 | 11.69 |
| Shareholders' funds (net worth) | 62.27 | 17.72 | 12.09 |
| Minority interest | 0.07 | 0.01 | 0.01 |
| Secured loans | 20.31 | 22.35 | 11.45 |
| Unsecured loans | 4.33 | 3.76 | 7.36 |
| Total debt | 24.64 | 26.11 | 18.81 |
| Total liabilities | 86.97 | 43.85 | 30.98 |
| Assets | |||
| Gross block | 11.37 | 11.73 | 16.81 |
| Net block | 11.34 | 11.70 | 10.47 |
| Capital work in progress | 3.91 | 0.00 | 2.66 |
| Investments | 0.00 | 0.00 | 0.00 |
| Inventories | 25.76 | 23.67 | 12.13 |
| Sundry debtors | 67.39 | 49.31 | 32.07 |
| Cash & bank balances | 8.80 | 0.28 | 3.00 |
| Loans & advances | 11.37 | 10.66 | 6.34 |
| Total current assets | 113 | 83.92 | 53.54 |
| Total current liabilities | 48.07 | 53.91 | 37.33 |
| Net working capital | 65.25 | 30.01 | 16.21 |
| Total assets | 86.97 | 43.85 | 30.98 |
| Particulars | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|
| Opening cash | 0.28 | 0.33 | 1.85 |
| Net cash from operating activities | (13.01) | (4.77) | 5.15 |
| Net cash from investing activities | 26.00 | (0.27) | (5.24) |
| Net cash from financing activities | (4.47) | 4.99 | 1.24 |
| Net change in cash | 8.52 | (0.05) | 1.15 |
| Closing cash | 8.80 | 0.28 | 3.00 |
| Particulars | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|
| Growth | |||
| Sales growth | +14.9% | +24.9% | - |
| EBITDA growth | +70.8% | +30.0% | - |
| PBT growth | +102.1% | +51.1% | +9997.0% |
| Net income growth | +116.0% | +55.6% | - |
| Profitability & leverage | |||
| Net income margin | +7.3% | +4.3% | +3.4% |
| Return on capital employed | +25.2% | +24.0% | +21.5% |
| Return on net worth | +24.1% | +32.7% | +25.9% |
| Debt / equity | 0.63 | 1.51 | 1.56 |
| Long-term debt / equity | 0.21 | 0.63 | 0.87 |
| Interest cover | 21.19 | 30.10 | 39.79 |
| Efficiency & per share | |||
| Fixed asset turnover | 12.67 | 8.98 | 5.45 |
| Inventory turnover | 5.92 | 7.16 | 7.56 |
| Debtors turnover | 2.51 | 3.15 | 2.86 |
| EPS (₹) | 5.59 | 122.02 | 78.46 |
| Dividend per share (₹) | 0.50 | 0.00 | 0.00 |
| Book value per share (₹) | 36.31 | 443.04 | 302.27 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 171 | 133 | 132 | 115 | 91.66 | 73.40 | 78.27 |
| Revenue growth | +28.4% | +1.3% | +14.9% | +24.9% | +24.9% | -6.2% | - |
| Other income | 5.10 | 2.61 | 2.12 | 1.24 | 0.95 | 0.11 | 0.06 |
| Total expenses | 159 | 120 | 116 | 105 | 84.65 | 66.21 | 71.23 |
| Employee cost | 7.47 | 6.76 | 5.34 | 4.96 | 2.98 | 2.41 | 3.00 |
| EBITDA | 11.94 | 13.34 | 15.47 | 9.05 | 7.01 | 7.19 | 7.04 |
| EBITDA margin | +7.0% | +10.0% | +11.8% | +7.9% | +7.7% | +9.8% | +9.0% |
| Depreciation | 6.05 | 2.97 | 1.30 | 1.30 | 1.34 | 1.22 | 0.92 |
| Interest | 5.61 | 3.71 | 3.00 | 2.33 | 2.21 | 1.49 | 1.31 |
| Profit before tax | 5.38 | 9.27 | 13.29 | 6.66 | 4.41 | 4.59 | 4.87 |
| Tax | 1.45 | 2.10 | 3.75 | 1.78 | 1.19 | 1.53 | 1.47 |
| Net profit | 4.10 | 7.36 | 10.65 | 4.88 | 3.22 | 3.06 | 3.39 |
| Net profit margin | +2.4% | +5.5% | +8.1% | +4.3% | +3.5% | +4.2% | +4.3% |
| EPS (₹) | 2.30 | 4.18 | 5.56 | 122.03 | 80.32 | 76.66 | 85.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 17.15 | 17.15 | 17.15 | 0.40 | 0.40 | 0.40 | 0.40 |
| Reserves & surplus | 56.17 | 52.23 | 45.07 | 17.33 | 12.45 | 9.24 | 6.17 |
| Shareholders' funds (net worth) | 73.32 | 69.38 | 62.22 | 17.73 | 12.85 | 9.64 | 6.57 |
| Secured loans | 47.58 | 47.58 | 20.31 | 2.97 | 11.95 | 10.68 | 7.10 |
| Unsecured loans | 7.52 | 0.99 | 3.63 | 22.45 | 4.84 | 4.80 | 4.97 |
| Total debt | 55.10 | 48.57 | 23.94 | 25.42 | 16.79 | 15.48 | 12.07 |
| Total liabilities | 128 | 118 | 86.15 | 43.15 | 29.64 | 25.12 | 18.64 |
| Assets | |||||||
| Gross block | 55.11 | 52.18 | 19.90 | 18.48 | 16.80 | 14.23 | 10.19 |
| Net block | 37.24 | 40.26 | 10.94 | 10.82 | 10.45 | 9.22 | 6.40 |
| Capital work in progress | 13.82 | 3.10 | 3.91 | 0.00 | 0.00 | 0.00 | 2.61 |
| Investments | 0.00 | 0.00 | 0.03 | 0.03 | 0.03 | 0.00 | 0.00 |
| Inventories | 42.42 | 39.61 | 25.76 | 23.67 | 12.13 | 6.83 | 4.36 |
| Sundry debtors | 73.35 | 60.58 | 67.39 | 49.31 | 32.07 | 23.39 | 25.43 |
| Cash & bank balances | 0.26 | 0.26 | 8.74 | 0.20 | 2.89 | 1.85 | 0.44 |
| Loans & advances | 12.92 | 12.02 | 10.94 | 10.90 | 6.70 | 3.78 | 4.48 |
| Total current assets | 129 | 112 | 113 | 84.08 | 53.79 | 35.85 | 34.71 |
| Total current liabilities | 59.09 | 43.53 | 48.02 | 53.90 | 36.33 | 21.14 | 24.98 |
| Net working capital | 69.86 | 68.94 | 64.81 | 30.18 | 17.46 | 14.71 | 9.73 |
| Total assets | 128 | 118 | 86.15 | 43.15 | 29.64 | 25.12 | 18.64 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.26 | 8.74 | 0.20 | 0.21 | 1.85 | 0.44 | 0.53 |
| Net cash from operating activities | 8.87 | (5.47) | (15.84) | (4.27) | 4.91 | (0.89) | 3.48 |
| Net cash from investing activities | (13.71) | (31.41) | (5.33) | (2.05) | (3.04) | (2.22) | (4.93) |
| Net cash from financing activities | 4.83 | 28.39 | 29.72 | 6.30 | (0.83) | 2.88 | 1.36 |
| Net change in cash | 0.00 | (8.48) | 8.55 | (0.01) | 1.04 | (0.23) | (0.09) |
| Closing cash | 0.26 | 0.26 | 8.74 | 0.20 | 2.89 | 1.85 | 0.44 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +28.4% | +1.3% | +14.9% | +24.9% | +24.9% | -6.2% | - |
| EBITDA growth | -10.5% | -13.8% | +70.9% | +29.1% | -2.5% | +2.1% | - |
| PBT growth | -42.0% | -30.3% | +99.6% | +51.0% | -3.9% | -5.8% | +9997.0% |
| Net income growth | -44.3% | -30.9% | +118.2% | +51.6% | +5.2% | -9.7% | - |
| Revenue CAGR (3Y) | +14.4% | +13.3% | +21.5% | +13.5% | - | - | - |
| EBITDA CAGR (3Y) | +9.7% | +23.9% | +29.1% | +8.7% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +2.3% | +5.4% | +7.3% | +4.3% | +3.5% | +4.2% | +4.3% |
| Return on capital employed | +8.9% | +12.7% | +27.6% | +24.7% | +24.1% | +27.8% | +33.2% |
| Return on net worth | +5.5% | +10.9% | +26.6% | +31.9% | +28.6% | +37.9% | +51.8% |
| Debt / equity | 0.73 | 0.55 | 0.62 | 1.38 | 1.43 | 1.70 | 1.84 |
| Long-term debt / equity | 0.23 | 0.16 | 0.19 | 0.47 | 0.62 | 0.81 | 0.89 |
| Interest cover | 95.25 | 35.78 | 21.17 | 30.06 | 38.98 | 24.96 | 21.41 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 3.41 | 4.09 | 7.63 | 6.49 | 5.91 | 6.64 | 8.43 |
| Inventory turnover | 4.46 | 4.51 | 5.92 | 6.40 | 9.67 | 14.50 | 19.71 |
| Debtors turnover | 2.73 | 2.31 | 2.51 | 2.81 | 3.31 | 3.32 | 3.38 |
| EPS (₹) | 2.30 | 4.18 | 5.56 | 122.03 | 80.32 | 76.66 | 85.00 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 42.76 | 40.46 | 36.28 | 443.30 | 321.27 | 240.95 | 164.29 |
To see the full year-wise statements and ratios of Zenith Drugs Limited, buy the company report.
Board of directors of Zenith Drugs Limited
Zenith Drugs has 6 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sandeep Bhardwaj Also directs: My Med Private Limited | Managing Director | 31 Oct 2003 | 22 Years 11 Months | Current |
| Bhupesh Soni Also directs: My Med Private Limited | Director | 15 Mar 2001 | 25 Years 7 Months | Current |
| Ajay Singh Dassundi Also directs: My Med Private Limited | Director | 25 Jun 2015 | 11 Years 4 Months | Current |
| Ranjana Sureshkumar Sehgal | Director | 16 Sep 2023 | 3 Years 1 Months | Current |
| Anil Malik | Director | 25 Sep 2023 | 3 Years 1 Months | Current |
| Deendayal Kumawat | Director | 25 Sep 2023 | 3 Years 1 Months | Current |
Peer comparison
Zenith Drugs Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Zenith Drugs Limitedthis company | ₹171.22 Cr (FY 2026) | ₹4.1 Cr | 2.4% | 28.4% | Indore, Madhya Pradesh, India | |
| M.M. Remedies Private Limited | ₹137.33 Cr (FY 2025) | 10.0% | Llucknow, Uttar Pradesh, India | |||
| Palsons Derma Private Limited | ₹137.11 Cr (FY 2025) | 15.0% | Kolkata, West Bengal, India | |||
| Maxwell Life Science Limited | ₹136.55 Cr (FY 2025) | 67.0% | Mumbai, Maharashtra, India | |||
| Lewens Labs Private Limited | ₹136.52 Cr (FY 2025) | 12.0% | Bharuch, Gujarat, India | |||
| Naari Pharma Private Limited | ₹136.35 Cr (FY 2025) | 14.0% | Bangalore, Karnataka, India | |||
| Alpa Laboratories Limited | ₹135.8 Cr (FY 2025) | 10.0% | Indore, Madhya Pradesh, India | |||
| Ravoo's Laboratories Limited | ₹134.97 Cr (FY 2024) | 4.0% | Hyderabad, Telangana, India | |||
| Surabhi Industries (India) Private Limited | ₹133.75 Cr (FY 2024) | -37.0% | Hyderabad, Telangana, India | |||
| Vikram Thermo (India) Limited | ₹133.72 Cr (FY 2025) | 5.0% | Ahmedabad, Gujarat, India | |||
| Strassenburg Pharmaceuticals Private Ltd. | ₹133.69 Cr (FY 2025) | 13.0% | Kolkata, West Bengal, India |
To see the full peer comparison of Zenith Drugs Limited, buy the company report.
Charges & borrowings
Open charges
₹117.89 Cr
Satisfied charges
₹109.84 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 10 Jul 2026 | 101352306 | Sbicap Trustee Company Limited | ₹7 Cr | Open | |
| 22 Sep 2025 | 101184755 | Sidbi | ₹92 Lakh | Open | |
| 26 Mar 2025 | 101074698 | Sidbi | ₹2.03 Cr | Open | |
| 10 Mar 2025 | 101071178 | Sbicap Trustee Company Limited | ₹76.98 Cr | Open | |
| 17 Oct 2024 | 101007355 | Others | ₹51.86 Lakh | Open |
To see the full charge records of Zenith Drugs Limited, buy the company report.
Total charge records: 23 View all charges
Deals & funding
Zenith Drugs Limited has 1 deal on record (1 ipo); the latest was in February 2024.
Total deals
1
IPO
1
Deals on record (1 of 1)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Feb 2024 | IPO | ₹40.68 Cr | Investors: Meru Investment Fund PCC – Cell 1, Aries Opportunities Fund, Vikasa India EIF I Fund |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Zenith Drugs Limited has 7 court cases on record: 4 filed by Zenith Drugs, 3 filed against it. 6 cases are pending and 1 is disposed.
Total cases
7
Filed by the company
4
Filed against the company
3
Pending
6
Disposed
1
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 5 | 3 | 5 |
| High courts | 2 | 0 | 1 |
Cases on record (5 of 7)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Gadchiroli, Maharashtra | Civil suit | Filed against the company | Pending |
| District court, West Garo Hills, Meghalaya | Court case (Complaint Registration) | Filed against the company by State | Pending |
| District court, Indore, Madhya Pradesh | Court case (UN CR) | Filed against the company by Union of India Reptresented by Drugs Inspector | Pending |
| District court, Indore, Madhya Pradesh | Court case (UN CR) | Filed by the company against an individual | Pending |
| District court, Indore, Madhya Pradesh | Court case (SC NIA) | Filed by the company against an individual | Pending |
To see the full case history of Zenith Drugs Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Zenith Drugs Limited was last rated by Crisil on 30 Jan 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 30 Jan 2020 |
To see the full credit ratings and regulatory alerts of Zenith Drugs Limited, buy the company report.
MSME payment delays
Zenith Drugs Limited has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 218 overdue payments to 12 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 12)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Sarthak Pet Industries (India) Private Limited | |||
| Ascent Multi Forms Pvt Ltd | |||
| Vyanketesh Corrugators Pvt.Ltd. | |||
| an individual supplier | |||
| Libra Bioscience Private Limited |
To see the full MSME payment records of Zenith Drugs Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
Zenith Drugs has 6 GST registrations: 4 active and 2 cancelled or inactive.
Total GSTINs
6
Active
4
Cancelled / inactive
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 23AAACZ1475F1ZI | Madhya Pradesh | Active | 01 Jul 2017 |
| 19AAACZ1475F1Z7 | West Bengal | Active | 11 Feb 2021 |
| 06AAACZ1475F1ZE | Haryana | Active | 26 Mar 2021 |
| 32AAACZ1475F1ZJ | Kerala | Active | 25 Jun 2024 |
To see the full GST registrations and return filing status of Zenith Drugs Limited, buy the company report.
Recent activity
Zenith Drugs Limited has 8 board changes on record since 2001: 6 appointments and 2 cessations. The latest: Anil Malik was appointed as Director on 25 Sep 2023.
Charges
A charge with Sbicap Trustee Company Limited of Rs. 7.00 Cr registered on 10 Jul 2026 with Charge ID 101352306 was modified on 17 Jul 2026.
Charges
A charge with Sbicap Trustee Company Limited amounted to Rs. 7.00 Cr with Charge ID 101352306 was registered on 10 Jul 2026.
Filing
Zenith Drugs Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Gwalior.
AGM
Zenith Drugs Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Charges
A charge with Sidbi amounted to Rs. 0.92 Cr with Charge ID 101184755 was registered on 22 Sep 2025.
Charges
A charge with Sidbi amounted to Rs. 2.03 Cr with Charge ID 101074698 was registered on 26 Mar 2025.
Charges
A charge registered on 19 Oct 2024 via Charge ID 101000220 with State Bank Of India was fully satisfied on 20 Mar 2025.
Charges
A charge with Sbicap Trustee Company Limited of Rs. 76.98 Cr registered on 10 Mar 2025 with Charge ID 101071178 was modified on 12 Mar 2025.
Charges
A charge with Sbicap Trustee Company Limited amounted to Rs. 76.98 Cr with Charge ID 101071178 was registered on 10 Mar 2025.
Charges
A charge registered on 16 Jun 2023 via Charge ID 100752532 with Others was fully satisfied on 07 Mar 2025.
Charges
A charge registered on 02 Feb 2023 via Charge ID 100678958 with Others was fully satisfied on 07 Mar 2025.
Charges
A charge with State Bank Of India amounted to Rs. 75.15 Cr with Charge ID 101000220 was registered on 19 Oct 2024.
40 earlier events are in the company report.
News
Frequently asked questions
Zenith Drugs is an active public limited company based in Indore, Madhya Pradesh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 15 November 2000 (26+ years old) and is registered under CIN L24231MP2000PLC014465. Listed on NSE: ZENITHDRUG.
Zenith Drugs reported revenue of ₹171.22 Cr for FY 2025-26 (up 28.4% YoY) based on standalone financials.
Zenith Drugs has 6 current directors:
- Sandeep Bhardwaj - Managing Director
- Bhupesh Soni - Director
- Ajay Singh Dassundi - Director
- Ranjana Sureshkumar Sehgal - Director
- Anil Malik - Director
- Deendayal Kumawat - Director
The latest financial statements of Zenith Drugs on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Zenith Drugs is 23AAACZ1475F1ZI, registered in Madhya Pradesh. The company has 6 GST registrations in all, of which 4 are active and 2 are cancelled or inactive. Other active GSTINs include 19AAACZ1475F1Z7 (West Bengal), 06AAACZ1475F1ZE (Haryana), 32AAACZ1475F1ZJ (Kerala).
The CIN (Corporate Identification Number) of Zenith Drugs is L24231MP2000PLC014465. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Zenith Drugs is a listed company as per MCA records. Its shares are listed on NSE (symbol: ZENITHDRUG).
Zenith Drugs has 7 court cases on record: 4 filed by the company and 3 filed against it. 6 are pending. Most are in the district courts.
Zenith Drugs was incorporated on 15 November 2000, making it 26+ years old. It is registered with the Registrar of Companies, Gwalior.
Zenith Drugs has 1 deal on record (1 ipo); the latest was in February 2024.
The peers of Zenith Drugs by revenue are M.M. Remedies Private Limited, Palsons Derma Private Limited, Maxwell Life Science Limited, Lewens Labs Private Limited, Naari Pharma Private Limited and 5 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Anil Malik was appointed as Director on 25 Sep 2023. Deendayal Kumawat was appointed as Director on 25 Sep 2023. Ranjana Sureshkumar Sehgal was appointed as Director on 16 Sep 2023. Zenith Drugs has 8 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages